CDH1 and neoplasm: Most tumours (49, 89%) presented a lost/low expression of the E-cadherin; all 8 PTC-A cases (100%) presented a lower expression of E-cadherin, while 3 out of 20 PDTC/ATC cases (15%) retained its expression (Table 4; Figure 2).